SAT0181 Low dose interleukin-2 combined with tocilizumab selectively increases regulatory t cells helping refractory rheumatoid arthritis patients achieve remission more rapidly

Abstract

BackgroundRheumatoid arthritis (RA) is a prevalent chronic autoimmune inflammatory disease. Its pathogenesis is closely associated with a failure of endogenous immune tolerance that caused by the imbalance of pro-inflammatory T...